WO2018118941A1 - Amino acid compositions and methods for the treatment of liver diseases - Google Patents

Amino acid compositions and methods for the treatment of liver diseases Download PDF

Info

Publication number
WO2018118941A1
WO2018118941A1 PCT/US2017/067345 US2017067345W WO2018118941A1 WO 2018118941 A1 WO2018118941 A1 WO 2018118941A1 US 2017067345 W US2017067345 W US 2017067345W WO 2018118941 A1 WO2018118941 A1 WO 2018118941A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
composition
acid entity
entity
nac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2017/067345
Other languages
English (en)
French (fr)
Inventor
Michael HAMILL
Raffi AFEYAN
Chung-Wei Lee
Harry LUITHARDT
David Berry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axcella Health Inc
Original Assignee
Axcella Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2017382170A priority Critical patent/AU2017382170B2/en
Priority to EP17829105.0A priority patent/EP3554492A1/en
Priority to EA201991502A priority patent/EA201991502A1/ru
Priority to JP2019533079A priority patent/JP2020504108A/ja
Priority to CN201780078656.7A priority patent/CN110087647B/zh
Priority to CU2019000058A priority patent/CU20190058A7/es
Priority to KR1020197020657A priority patent/KR20190099242A/ko
Priority to MX2019007351A priority patent/MX2019007351A/es
Priority to IL296614A priority patent/IL296614A/en
Priority to CA3046551A priority patent/CA3046551A1/en
Priority to CN202211400026.6A priority patent/CN115814053A/zh
Application filed by Axcella Health Inc filed Critical Axcella Health Inc
Priority to BR112019012529-9A priority patent/BR112019012529A2/pt
Publication of WO2018118941A1 publication Critical patent/WO2018118941A1/en
Priority to ZA2019/03580A priority patent/ZA201903580B/en
Priority to CONC2019/0006291A priority patent/CO2019006291A2/es
Priority to IL267480A priority patent/IL267480B/en
Priority to PH12019501414A priority patent/PH12019501414A1/en
Anticipated expiration legal-status Critical
Priority to IL284371A priority patent/IL284371B2/en
Priority to JP2022193127A priority patent/JP2023029946A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/0634—N-Acetyl-Cysteine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the wt. ratio of the L-amino acid entity, the R-amino acid entity, the L-glutamine or a salt thereof, and the NAC or salt thereof is about 0.5 to 3 : 0.5 to 4 : 1 to 4 : 0.1 to 2.5, e.g., the wt. ratio of the L-amino acid entity, the R- amino acid entity, the L-glutamine or a salt thereof, and the NAC or salt thereof is about 1 : 1.5 : 2 : 0.15 or about 1 : 1.5 : 2 : 0.3. In certain embodiments, the wt.
  • the branched-chain amino acid is leucine, isoleucine, and valine.
  • Another aspect of the invention features a dietary composition including the composition of any one of the foregoing aspects or embodiments, e.g., wherein the dietary composition is chosen from a medical food, a functional food, or a supplement.
  • the subject has pediatric NAFLD. In some embodiments, the patient has steatosis.
  • the subject has non-alcoholic steatohepatitis (NASH).
  • NASH non-alcoholic steatohepatitis
  • the subject has cirrhosis.
  • the subject has type 2 diabetes.
  • the subject has hepatocarcinoma, an increased risk of liver failure, or an increased risk of death.
  • administering the composition results in an improvement in one or more metabolic symptoms in the subject.
  • the improvement in one or more metabolic symptoms is selected from the following: increased free fatty acid and lipid metabolism, improved mitochondrial function, white adipose tissue (WAT) browning, decreased reactive oxygen species (ROS), increased levels of glutathione (GSH), decreased hepatic inflammation, decreased hepatocyte ballooning, improved gut barrier function, increased insulin secretion, or improved glucose tolerance.
  • (a) is a L- amino acid entity dipeptide or a salt thereof (e.g., a L-leucine dipeptide or a salt thereof).
  • (a) is a homodipeptide.
  • (a) is a heterodipeptide, e.g., Ala-Leu.
  • composition satisfies the properties of (gg)-(ii) defined above.
  • nn a combination of two or three of (kk)-(mm).
  • the composition satisfies the properties of (kk)-(mm) defined above. In certain embodiments, the composition satisfies the properties of at least 2, 3, or 4 of any of properties (kk)-(nn) defined above.
  • ratio of the R-amino acid entity to the S-amino acid entity or a salt thereof is greater than 1:4, greater than 1:3, about 1:2, or about 9:20, and not more than 1.5:2 or 1: 1, e.g., the ratio of the R-amino acid entity to the S-amino acid entity is about 1:2, or the ratio of the R-amino acid entity to the S-amino acid entity is about 9:20; or 22) a combination of two or three of (19)-(21).
  • the composition further comprises one or both of L-glycine and L-serine.
  • the composition comprises an L- amino acid entity, an I-amino acid entity, an V-amino acid entity, an R-amino acid entity, an L-glutamine or a salt thereof, an NAC or a salt thereof, and an L-glycine.
  • the composition comprises an L-amino acid entity, an I- amino acid entity, an V-amino acid entity, an R-amino acid entity, an L-glutamine or a salt thereof, an NAC or a salt thereof, and an L-serine.
  • the wt. ratio of the L-amino acid entity, the I-amino acid entity, the V-amino acid entity, the R-amino acid entity, the L-glutamine or salt thereof, and the NAC or salt thereof is about 1 : 0.5: 0.5: 1.5 : 2 : 0.15, about 1 : 0.5: 0.5: 1.5 : 2 : 0.225, about 1 : 0.5: 0.5: 1.5 : 2 : 0.3, or about 1 : 0.5: 0.5: 1.5 : 2 : 0.5.
  • the composition comprises about 4 g of the L-amino acid entity, about 2 g of the I- amino acid entity, about 1 g of V-amino acid entity, about 3 g of R-amino acid entity, about 4 g of L-glutamine or a salt thereof, about 0.9 g of NAC or a salt thereof, about 3 g of L-serine or a salt thereof, and about 3 g of L-glycine or a salt thereof.
  • L-Valine is provided as part of a dipeptide comprising L- Valine, or a salt thereof, or a tripeptide comprising L- Valine, or a salt thereof.
  • NAC is provided as a part of a dipeptide comprising NAC, or a salt thereof, or a tripeptide comprising NAC, or a salt thereof.
  • Another aspect of the invention features a method for treating fatty liver disease, wherein the method comprises administering to a subject in need thereof an effective amount of a composition comprising:
  • the subject has a disease or disorder selected from the group consisting of non-alcoholic fatty liver (NAFL), non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic fatty liver disease (AFLD), and alcoholic steatohepatitis (ASH).
  • NAFL non-alcoholic fatty liver
  • NAFLD non-alcoholic fatty liver disease
  • NASH non-alcoholic steatohepatitis
  • AFLD alcoholic fatty liver disease
  • ASH alcoholic steatohepatitis
  • the subject has pediatric NAFLD.
  • the subject exhibits muscle atrophy or has a decreased ratio of muscle tissue to adipose tissue relative to a normal subject, e.g., without the one or more symptoms or without a fatty liver disease, e.g., the subject exhibits muscle atrophy without one or both of fibrosis or cirrhosis.
  • FIGS. 1A-1B are graphs showing the effect of treatment with an amino acid composition (Amino Acid Composition A-l) on the NAFLD activity score, ballooning, and fibrosis in the STAM mouse model (FIG. 1A) and in the FATZO mouse model (FIG. IB).
  • FIG. 2 is a schematic showing the metabolic symptoms of patients with non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and cirrhosis prior to administration of a composition comprising amino acid entities described herein (top) and the improvement in patients with NAFLD, NASH, and cirrhosis after administration of the composition (bottom).
  • NAFLD non-alcoholic fatty liver disease
  • NASH non-alcoholic steatohepatitis
  • FIGS. 1A-1B are graphs showing the effect of treatment with an amino acid composition (Amino Acid Composition A-l) on the NAFLD activity score, ballooning, and fibrosis in the STAM mouse model (FIG
  • the amino acid entity composition may be administered to the subject for a treatment period of, e.g., two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, or longer at a dose of about 15 total grams per day to about 90 total grams per day (e.g., a total of about 48 g or a total of about 72 g per day).
  • NAFL NAFL
  • AFLD e.g., ASH
  • “About” and “approximately” shall generally mean an acceptable degree of error for the quantity measured given the nature or precision of the measurements. Exemplary degrees of error are within 20 percent (%), typically, within 10%, and more typically, within 5% of a given value or range of values.
  • a "pharmaceutical composition” described herein comprises at least one amino acid and a pharmaceutically acceptable carrier or excipient.
  • the pharmaceutical composition is used as a therapeutic, a nutraceutical, a medical food, or as a supplement.
  • compositions, formulation or product refers to amino acids, materials, excipients, compositions and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • a composition, formulation or product is "therapeutic” if it provides a beneficial clinical effect. A beneficial clinical effect can be shown by lessening the progression of a disease and/or alleviating one or more symptoms of the disease.
  • Amino acid entities include amino acids, precursors, metabolites, and derivatives of the compositions described herein.
  • the composition further comprises one or two additional branched-chain amino acid (BCAA)-entities, e.g., one or both of an isoleucine (I)-amino acid- entity and a valine (V)-amino acid-entity.
  • BCAA branched-chain amino acid
  • I isoleucine
  • V valine
  • both the I-amino acid-entity and the V-amino acid-entity are present.
  • the L-entity is present at a higher amount (% by weight) than one or both of the I-amino acid-entity and the V-amino acid- entity (e.g., the L-entity is present at an amount of at least 10 wt. %, at least 15 wt. %, at least 20 wt.
  • the composition comprises a combination of 2 to
  • the BCAA is leucine.
  • the BCAA is leucine, isoleucine, and valine.
  • the amino acids leucine, isoleucine, valine, arginine HCl, glutamine and N-acetylcysteine are present in a weight ratio of about 1 : 0.5 : 0.5 : 1.5 : 2 : 0.1 to 0.3. In some embodiments, the amino acids leucine, isoleucine, valine, arginine HCl, glutamine and N-acetylcysteine are present in a weight ratio of about 1 : 0.5 : 0.5 : 1.5 : 2 : 0.25.
  • a total weight (wt) of the amino acids is about 2 g to about 60 g.
  • the composition includes about 1 g of leucine, about 0.5 g of isoleucine, about 0.5 g of valine, about 1.5 g of arginine (or 1.81 g of arginine HCl), about 2 g of glutamine, and about 0.15 g of N-acetylcysteine.
  • Table 4 Exemplary amino acid components of the composition including Arginine.
  • An exemplary Amino Acid Composition includes leucine, isoleucine, valine, arginine, glutamine, and N-acetylcysteine as its amino acid entities in a wt. ratio of 1 : 0.5 : 0.5 : 0.75 : 2 : 0.15 (Table 6). Table 5. Exemplary amino acid components of the composition including Arginine HCl.
  • An exemplary Amino Acid Composition includes leucine, isoleucine, valine, arginine HCl, glutamine, N-acetylcysteine, and serine as its amino acid entities in a wt. ratio of 1 : 0.5 : 0.25 : 0.905 : 1 : 0.225 : 0.667 (Table 11).
  • An exemplary Amino Acid Composition includes leucine, isoleucine, valine, arginine, glutamine, N-acetylcysteine, and serine as its amino acid entities in a wt. ratio of 1 : 0.5 : 0.25 : 0.75 : 1 : 0.225 : 1.667 (Table 12).
  • the composition that decreases and/or prevents steatosis comprises one or more BCAAs, one or more CEAAs, and an antioxidant or ROS scavenger.
  • the composition comprises a coloring agent.
  • suitable color agents include food, drug and cosmetic colors (FD&C), drug and cosmetic colors (D&C), and external drug and cosmetic colors (Ext. D&C).
  • the coloring agents can be used as dyes or their corresponding lakes.
  • the composition reduces or inhibits liver fibrosis in a subject with NAFLD (e.g., a subject with pediatric NAFLD). In some embodiments, the composition reduces or inhibits liver fibrosis in a subject with NAFLD (e.g., a subject with pediatric NAFLD).
  • administration of the composition results in increased free fatty acid and lipid metabolism in a subject with NASH (e.g., a subject with NAFLD, fibrosis, and type 2 diabetes). In some embodiments, administration of the composition results in improved mitochondrial function in a subject with NASH. In some embodiments, administration of the composition results in white adipose tissue (WAT) browning in a subject with NASH (e.g., a subject with NAFLD, fibrosis, and type 2 diabetes).
  • WAT white adipose tissue
  • administration of the composition results in increased insulin secretion in a subject with cirrhosis (e.g., a subject with hepatocarcinoma, increased risk of liver failure, and increased risk of death). In some embodiments, administration of the composition results in improved glucose tolerance in a subject with cirrhosis (e.g., a subject with
  • the composition is administered at a dose of about 20 g to about 40 g total amino acids, e.g., once per day, twice per day, three times per day, four times per day, five times per day, or six times per day (e.g., three times per day).
  • the composition is administered at a dose of about 24 g total amino acids, e.g., once per day, twice per day, three times per day, four times per day, five times per day, or six times per day (e.g., three times per day).
  • the composition is administered at a dose of about 24 g total amino acids three times per day.
  • the composition includes at least 1 g of leucine, at least 0.5 g of isoleucine, at least 0.5 g of valine, at least 0.75 g of arginine (or 0.905 g of arginine HCl), at least 2 g of glutamine, and at least 0.15 g of N-acetylcysteine for administration three times per day (e.g., for a total of at least 18 g per day).
  • the composition includes about 1 g of leucine, about 0.5 g of isoleucine, about 0.25 g of valine, about 0.75 g of arginine (or 0.905 g of arginine HCl), about 1 g of glutamine, and about 0.225 g of N-acetylcysteine for administration three times per day (e.g., for a total of about 18 g per day).
  • administration of the dietary composition results in an
  • TIMP1 tissue inhibitor of metalloproteinase
  • TIMP2 tissue inhibitor of metalloproteinase
  • MMP matrix metalloproteinase
  • composition comprises L-leucine, a R-amino acid entity, a Q-amino acid entity, and homocysteine.
  • composition of embodiment 1-lD, 4, or 136, wherein the composition comprises HMB, a R-amino acid entity, a Q-amino acid entity, and serine.
  • composition of embodiment 1-lD, 4, or 136, wherein the composition comprises HMB, a R-amino acid entity, a Q-amino acid entity, and L-cysteine.
  • composition of embodiment 1-lD, 4, or 136 wherein the composition comprises HMB, a R-amino acid entity, glutamate, and serine.
  • composition of embodiment 1- lD, 4, or 136 wherein the composition comprises HMB, a R-amino acid entity, carbamoyl-P, and acetylserine.
  • composition of embodiment 1-lD, 4, or 136 wherein the composition comprises HMB, D-arginine, a Q-amino acid entity, and L-cysteine.
  • composition of embodiment 1-lD, 4, or 136 wherein the composition comprises HMB, N-acetyl-arginine, argininosuccinate, and cystine.
  • composition of embodiment 1-lD, 4, or 197 wherein the composition comprises isovaleryl-CoA, glutamate, a Q-amino acid entity, and an antioxidant or ROS scavenger, e.g., a NAC entity.
  • composition of embodiment 1-lD, 4, or 197, wherein the composition comprises isovaleryl-CoA, citrulline, D-glutamine, and an antioxidant or ROS scavenger, e.g., a NAC entity.
  • composition of embodiment 1-lD, 4, or 197, wherein the composition comprises isovaleryl-CoA, aspartate, N-acetyl-glutamine, and an antioxidant or ROS scavenger, e.g., a NAC entity.
  • composition of embodiment 1-lD, 4, or 197, wherein the composition comprises isovaleryl-CoA, creatine, D-glutamine and D-cysteine.
  • composition of embodiment 1-lD, 5, or 258, wherein the composition comprises D-leucine, a R-amino acid entity, L-glutamine, and L-cysteine. 308.
  • composition of embodiment 1-lD, 5, or 258, wherein the composition comprises D-leucine, a R-amino acid entity, a glutamate, and cystine.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PCT/US2017/067345 2016-12-19 2017-12-19 Amino acid compositions and methods for the treatment of liver diseases Ceased WO2018118941A1 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
CN202211400026.6A CN115814053A (zh) 2016-12-19 2017-12-19 氨基酸组合物及肝疾病的治疗方法
EA201991502A EA201991502A1 (ru) 2017-10-24 2017-12-19 Композиции на основе аминокислот и способы лечения заболеваний печени
JP2019533079A JP2020504108A (ja) 2016-12-19 2017-12-19 アミノ酸組成物および肝疾患の治療方法
CN201780078656.7A CN110087647B (zh) 2016-12-19 2017-12-19 氨基酸组合物及肝疾病的治疗方法
CU2019000058A CU20190058A7 (es) 2016-12-19 2017-12-19 Composiciones de aminoácidos relacionadas con mejoras de la función hepática
KR1020197020657A KR20190099242A (ko) 2016-12-19 2017-12-19 아미노산 조성물 및 간 질환의 치료 방법
MX2019007351A MX2019007351A (es) 2016-12-19 2017-12-19 Composiciones de aminoacidos y metodos de tratamiento de enfermedades hepaticas.
IL296614A IL296614A (en) 2016-12-19 2017-12-19 Amino acid compounds and methods for treating liver diseases
BR112019012529-9A BR112019012529A2 (pt) 2016-12-19 2017-12-19 composições de aminoácido e métodos para o tratamento de doenças hepáticas
AU2017382170A AU2017382170B2 (en) 2016-12-19 2017-12-19 Amino acid compositions and methods for the treatment of liver diseases
EP17829105.0A EP3554492A1 (en) 2016-12-19 2017-12-19 Amino acid compositions and methods for the treatment of liver diseases
CA3046551A CA3046551A1 (en) 2016-12-19 2017-12-19 Amino acid compositions and methods for the treatment of liver diseases
ZA2019/03580A ZA201903580B (en) 2016-12-19 2019-06-04 Amino acid compositions and methods for the treatment of liver diseases
CONC2019/0006291A CO2019006291A2 (es) 2016-12-19 2019-06-17 Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas
IL267480A IL267480B (en) 2016-12-19 2019-06-18 Amino acid compounds and methods for treating liver diseases
PH12019501414A PH12019501414A1 (en) 2016-12-19 2019-06-19 Amino acid compositions and methods for the treatment of liver diseases
IL284371A IL284371B2 (en) 2016-12-19 2021-06-24 Amino acid compounds and methods for treating liver diseases
JP2022193127A JP2023029946A (ja) 2016-12-19 2022-12-01 アミノ酸組成物および肝疾患の治療方法

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201662436073P 2016-12-19 2016-12-19
US62/436,073 2016-12-19
US201762443205P 2017-01-06 2017-01-06
US62/443,205 2017-01-06
US201762491773P 2017-04-28 2017-04-28
US62/491,773 2017-04-28
US201762545322P 2017-08-14 2017-08-14
US62/545,322 2017-08-14
US201762576267P 2017-10-24 2017-10-24
US62/576,267 2017-10-24

Publications (1)

Publication Number Publication Date
WO2018118941A1 true WO2018118941A1 (en) 2018-06-28

Family

ID=60957469

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/067345 Ceased WO2018118941A1 (en) 2016-12-19 2017-12-19 Amino acid compositions and methods for the treatment of liver diseases

Country Status (22)

Country Link
US (7) US11129804B2 (cg-RX-API-DMAC10.html)
EP (1) EP3554492A1 (cg-RX-API-DMAC10.html)
JP (2) JP2020504108A (cg-RX-API-DMAC10.html)
KR (1) KR20190099242A (cg-RX-API-DMAC10.html)
CN (2) CN115814053A (cg-RX-API-DMAC10.html)
AU (1) AU2017382170B2 (cg-RX-API-DMAC10.html)
BR (1) BR112019012529A2 (cg-RX-API-DMAC10.html)
CA (1) CA3046551A1 (cg-RX-API-DMAC10.html)
CL (1) CL2019001686A1 (cg-RX-API-DMAC10.html)
CO (1) CO2019006291A2 (cg-RX-API-DMAC10.html)
CU (1) CU20190058A7 (cg-RX-API-DMAC10.html)
EC (1) ECSP19043710A (cg-RX-API-DMAC10.html)
IL (3) IL296614A (cg-RX-API-DMAC10.html)
JO (1) JOP20190146A1 (cg-RX-API-DMAC10.html)
MA (1) MA51451A (cg-RX-API-DMAC10.html)
MX (2) MX2019007351A (cg-RX-API-DMAC10.html)
PE (1) PE20191136A1 (cg-RX-API-DMAC10.html)
PH (1) PH12019501414A1 (cg-RX-API-DMAC10.html)
SG (1) SG10201913946WA (cg-RX-API-DMAC10.html)
TW (1) TWI777999B (cg-RX-API-DMAC10.html)
WO (1) WO2018118941A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201903580B (cg-RX-API-DMAC10.html)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10201513B2 (en) 2016-12-19 2019-02-12 Axcella Health Inc. Amino acid compositions and methods for the treatment of liver diseases
WO2019036442A1 (en) * 2017-08-14 2019-02-21 Axcella Health Inc. AMINO ACIDS BRANCHED FOR THE TREATMENT OF NEURONAL INJURY
US10596136B2 (en) 2018-06-20 2020-03-24 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
US10660870B2 (en) 2017-08-14 2020-05-26 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting
WO2021020923A1 (ko) * 2019-07-30 2021-02-04 주식회사 고바이오랩 간 손상 예방, 개선, 또는 치료용 조성물 및 간 손상 예방, 개선, 또는 치료방법
KR20210014605A (ko) * 2019-07-30 2021-02-09 주식회사 고바이오랩 간 손상 예방, 개선, 또는 치료용 조성물
WO2022266480A1 (en) 2021-06-17 2022-12-22 Axcella Health Inc. Methods of predicting liver fat content and uses thereof
US11617731B2 (en) 2017-04-28 2023-04-04 Axcella Health, Inc. Amino acid compositions and their use for the treatment of traumatic brain injury
US20230203079A1 (en) * 2020-05-15 2023-06-29 Beijing Guanghe Original Technology Co., Ltd. Amino Acid Composition and Method for Catalytic Synthesis of Amino Acid by Means of Energy Radiation
RU2810601C2 (ru) * 2019-07-30 2023-12-27 Кобиолабс, Инк. Композиция и способ для предотвращения, снятия симптомов или терапевтического воздействия на поражение печени
WO2024026307A1 (en) 2022-07-25 2024-02-01 Axcella Health Inc. Biomarker for long covid and fatigue
WO2024030909A1 (en) 2022-08-01 2024-02-08 Axcella Health Inc. Biomarkers of amino acid composition treatment response in long covid

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11026991B2 (en) * 2018-04-18 2021-06-08 Ingenious Ingredients, LP Compositions and methods of use thereof to promote muscle growth and function
CU20200106A7 (es) 2018-06-20 2021-08-06 Axcella Health Inc Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
BR112020025831A2 (pt) 2018-06-20 2021-03-23 Axcella Health Inc. métodos de fabricação de composições de aminoácidos
US11980645B2 (en) 2019-01-22 2024-05-14 The Regents Of The University Of California Bile acids and use in disease treatment
CN110037221A (zh) * 2019-05-28 2019-07-23 广州阿米乐生物技术有限公司 一种解酒固体饮料及其制备方法
US20230105984A1 (en) * 2019-12-23 2023-04-06 Svetlana Marukian Compositions and methods for the treatment of liver diseases and disorders
JP7457827B2 (ja) * 2020-03-16 2024-03-28 武漢広行科学研究有限公司 肝硬変の治療のための銅クラスター及び組成物
US12636312B2 (en) 2020-03-16 2026-05-26 Wuhan Vast Conduct Science Foundation Co., Ltd. Gold clusters (AuCs), composition and method for treatment of liver cirrhosis
US11938152B2 (en) 2020-08-06 2024-03-26 Kedar N Prasad High-dose antioxidants in cancer treatment
CN112394178B (zh) * 2020-11-16 2022-08-05 首都医科大学附属北京朝阳医院 莫西沙星相关肝损伤的生物标志物、试剂盒及应用
US11737999B2 (en) * 2021-07-26 2023-08-29 Axcella Health Inc. Amino acid compositions and methods for the treatment of post-acute sequelae of COVID-19
US20250268855A1 (en) * 2022-04-25 2025-08-28 Fundació Eurecat Pharmaceutical and nutraceutical compositions with a combination of amino acids and its use in diseases characterized by lipid accumulation in tissues
KR20250159205A (ko) * 2023-03-03 2025-11-10 그래즈 이노베이션 지방산의 강화된 대사성 산화를 위한 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001056402A2 (en) * 2000-02-01 2001-08-09 Muscletech Research And Development Inc. Alpha lipoic acid based food supplement to increase lean muscle mass and strength
EP1541141A1 (en) * 2002-08-30 2005-06-15 Ajinomoto Co., Inc. Therapeutic agent for hepatic disease
WO2005084323A2 (en) * 2004-03-02 2005-09-15 Technical Sourcing International, Inc. Compositions of bio-active compounds from fenugreek seed and methods for producing same
WO2011097273A1 (en) * 2010-02-02 2011-08-11 Martek Biosciences Corporation Methods and compositions for treating non-alcoholic fatty liver disease with docosahexaenoic acid and n-acetyl lcystenine
EP2792354A2 (en) * 2011-03-16 2014-10-22 Obshchestvo S Ogranichennoj Otvetstvennostju «Biotekhnologii Pyshchino» Composition of protectors of acute and chronic hepatic encephalopathy and method for treating acute and chronic hepatic encephalopathy

Family Cites Families (328)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US693094A (en) 1900-08-13 1902-02-11 Hall Signal Co Signal and signaling-circuit.
US2457820A (en) 1945-12-27 1949-01-04 Merck & Co Inc Amino acid solution and process for preparing the same
US3012924A (en) 1956-12-17 1961-12-12 Libbey Owens Ford Glass Co Electrically conducting unit
GB1034358A (en) 1963-05-01 1966-06-29 Chugai Pharmaceutical Co Ltd Body-protein-biosynthesis promoting composition
US3832465A (en) 1971-12-09 1974-08-27 H Ghadimi Injectable amino acid composition commensurate to the anabolic need of the body and method of using same
US3988466A (en) 1973-06-01 1976-10-26 Kyowa Hakko Kogyo Co., Ltd. Prevention of gastric lesions
US3950529A (en) 1975-02-03 1976-04-13 Massachusetts General Hospital Amino acid formulations for patients with liver disease and method of using same
JPS5535049A (en) 1978-09-04 1980-03-11 Otsuka Pharmaceut Factory Inc Amino acid transfusion for cancerous patient
DE2906034C2 (de) 1979-02-16 1985-03-28 Maggi AG, Kempttal Verfahren zur Gewinnung von L-Leucin, L-Phenylalanin, L-Tyrosin, L-Cystin und von Gemischen aus L-Leucin und L-Isoleucin
US4898879A (en) 1981-06-29 1990-02-06 Baxter International Inc. Nurtitional composition for management of hepatic failure
CA1184499A (en) 1981-06-29 1985-03-26 David C. Madsen Nutritional composition for management of hepatic failure
JPS58126767A (ja) 1982-01-22 1983-07-28 Ajinomoto Co Inc 肝臓病患者用栄養組成物
US5298493A (en) 1983-04-20 1994-03-29 Clintec Nutrition Co. Compound for use in dietetics, reanimation and therapeutics containing protein fractions based on three types of minipeptides
CH658165A5 (fr) 1984-01-04 1986-10-31 Nestle Sa Produit alimentaire efficace dans le traitement de la lepre.
US5034377A (en) 1984-11-19 1991-07-23 Montefiore Hospital Association Of Western Pennsylvania Aqueous nutrient compositions comprising oligopeptides
JPS61186320A (ja) * 1985-02-12 1986-08-20 Morishita Seiyaku Kk アミノ酸製剤
US4871550A (en) 1986-09-05 1989-10-03 Millman Phillip L Nutrient composition for athletes and method of making and using the same
FR2618331B1 (fr) 1987-07-23 1991-10-04 Synthelabo Compositions pharmaceutiques utiles pour le traitement de l'uremie
US5028622A (en) 1988-05-06 1991-07-02 Ajinomoto Company, Inc. Administration of amino acids as treatment for neurodegenerative disorders
US5576351A (en) 1989-12-29 1996-11-19 Mcgaw, Inc. Use of arginine as an immunostimulator
AU650293B2 (en) 1990-11-01 1994-06-16 Nestec S.A. High acid system nutritional formulations
US5106836A (en) 1991-02-22 1992-04-21 Clintec Nutrition Co. Enteral diet
US5977073A (en) 1991-06-06 1999-11-02 Life Sciences' Technologies, Inc. Nutrient composition for treatment of immune disorders
US5780039A (en) 1992-04-23 1998-07-14 Novartis Nutrition Ag Orally-ingestible nutrition compositions having improved palatability
US5229136A (en) 1992-05-21 1993-07-20 Clintec Nutrition Co. Low caloric density enteral formulation designed to reduce diarrhea in tube-fed patients
US5276018A (en) 1992-07-17 1994-01-04 Brigham And Women's Hospital Composition comprising amino acids and methods for decreasing muscle breakdown
DE4229166A1 (de) 1992-09-01 1994-03-03 Deutsches Krebsforsch Mittel zur Aufrechterhaltung und/oder Steigerung der Muskelleistung und Körperzellmasse
US5356873A (en) 1992-11-05 1994-10-18 Clintec Nutrition Co. Method for providing nutritional requirements to patients having a chronic inflammation reaction
CA2143420C (en) 1992-12-23 1999-01-19 Phyllis J. B. Acosta Medical foods for the nutritional support of infant/toddler metabolic diseases
US5348979A (en) * 1992-12-23 1994-09-20 Iowa State University Research Foundation Inc. Method of promoting nitrogen retention in humans
US5571783A (en) 1993-03-09 1996-11-05 Clintec Nutrition Company Composition and method for treating patients with hepatic disease
US5891459A (en) 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
WO1995004529A1 (en) 1993-08-10 1995-02-16 Musashi Pty. Ltd. Composition for treatment of hangovers
US5438042B1 (en) 1993-10-08 1997-08-26 Sandoz Nutrition Ltd Enteral nutritional composition having amino acid profile
AU682894B2 (en) 1993-10-28 1997-10-23 Institut National De La Recherche Agronomique Composition based on amino acids intended for the treatment of sepsis or of an attack bringing about an inflammatory reaction, in animals and man
US5378722A (en) 1993-12-03 1995-01-03 Clintec Nutrition Co. Nutritional compositions for management of nitrogen metabolism
US5723446A (en) 1993-12-23 1998-03-03 Nestec Ltd. Enteral formulation designed for optimized nutrient absorption and wound healing
US5714472A (en) 1993-12-23 1998-02-03 Nestec Ltd. Enternal formulation designed for optimized nutrient absorption and wound healing
GB9403935D0 (en) 1994-03-01 1994-04-20 Sandoz Nutrition Ltd Improvements in or relating to organic compounds
US5719133A (en) 1994-09-21 1998-02-17 Novartis Nutrition Ag Adolescent dietary composition
IT1275434B (it) 1995-05-19 1997-08-07 Farmila Farma Milano Composizioni farmaceutiche e/o dietetiche ad attivita' antiossidante
US5728678A (en) 1995-06-06 1998-03-17 Nestec Ltd. Method and composition for providing nutrition to a renal failure patient
JP4280310B2 (ja) 1995-08-10 2009-06-17 佐々木化学工業株式会社 アミノ酸組成剤
US5733884A (en) 1995-11-07 1998-03-31 Nestec Ltd. Enteral formulation designed for optimized wound healing
US6087398A (en) 1996-03-01 2000-07-11 South Alabama Medical Science Foundation Sickle cell anemia treatment
US5716926A (en) 1996-07-26 1998-02-10 Paxton K. Beale Composition of pyruvate and protein and method for increasing protein concentration in a mammal
US6096785A (en) 1996-07-30 2000-08-01 Novartis Nutrition Ag Amino acid compositions and use thereof in treating renal dysfunction
JPH1053521A (ja) 1996-08-12 1998-02-24 Kagaku Gijutsu Shinko Jigyodan 脳内グルタミン酸の活性抑制剤および活性増強剤
US6544260B1 (en) 1996-08-20 2003-04-08 Oratec Interventions, Inc. Method for treating tissue in arthroscopic environment using precooling and apparatus for same
IT1289754B1 (it) 1996-12-16 1998-10-16 Professional Dietetics Srl Composizioni a base di aminoacidi
US6013273A (en) 1997-01-27 2000-01-11 Novartis Nutrition Ag Treatment of endotoxic shock
US5817329A (en) 1997-02-28 1998-10-06 Gardiner; Paul T. Nutritional supplement for increased muscle size and strength for body builders
EP1123013A1 (en) 1997-06-02 2001-08-16 Société des Produits Nestlé S.A. Product and method for providing glutamine
US5849335A (en) 1997-06-02 1998-12-15 Nestec S.A. Composition and method for providing glutamine
US6281244B1 (en) 1997-06-05 2001-08-28 Novartis Nutrition Ag Therapeutic use for glycine
ES2221095T3 (es) 1997-06-05 2004-12-16 Novartis Nutrition Ag Glicina para prevencion o tratamiento del rechazo de transplantes.
EP0891719A1 (en) 1997-07-14 1999-01-20 N.V. Nutricia Nutritional composition containing methionine
IT1294227B1 (it) 1997-08-01 1999-03-24 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l-carnitina e alcoli alifatici a lunga catena utile per la prevenzione
TW473387B (en) 1997-09-30 2002-01-21 Chugai Pharmaceutical Co Ltd Pharmaceutical or food compositions for treating hepatic diseases or improving liver functions
US6288116B1 (en) 1998-05-13 2001-09-11 Novartis Nutrition Ag Method of administration of a nutritional product to a person having renal failure
US6203820B1 (en) 1998-05-28 2001-03-20 Brice E. Vickery Compositions and methods for enhancing protein anabolism and detoxification
US6103748A (en) 1998-06-19 2000-08-15 Bryan; Thomas B. Method of treating an autoimmune disorder
US6031000A (en) 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
JP2000072669A (ja) 1998-08-24 2000-03-07 Inst Of Physical & Chemical Res アミノ酸・糖組成物
US6458338B1 (en) 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations
US20010041187A1 (en) 1998-10-20 2001-11-15 Carl W Hastings Performance-enhancing dietary supplement
EP1004302A3 (en) 1998-10-29 2003-06-04 Ajinomoto Co., Inc. Immunomodulator
US6051236A (en) 1998-11-12 2000-04-18 Pacifichealth Laboratories, Inc. Composition for optimizing muscle performance during exercise
US6143786A (en) 1999-02-02 2000-11-07 Novartis Nutrition Ag Oral arginine and insulin secretion
US6241996B1 (en) 1999-04-09 2001-06-05 Novartis Nutrition Ag Liquid soy nutritional products
HK1044100B (en) 1999-04-27 2005-07-22 Somalife Consulting Ltd. Supplement for restoring growth hormone levels
WO2001026642A2 (en) 1999-10-08 2001-04-19 Joyce Corinne Bechthold Methods and compositions for treating neurobehavioral disorders
GB9929497D0 (en) 1999-12-14 2000-02-09 Vitaflo Limited Improved amino acid mixtures for the treatment and/or management of certain diseases
US6833350B2 (en) 2000-02-04 2004-12-21 Nestec S.A. Method for maintaining or improving the synthesis of mucins
US6521591B1 (en) 2000-02-10 2003-02-18 N.V. Nutricia Pharmaceutical composition for muscular anabolism
GB0009056D0 (en) 2000-04-12 2000-05-31 Nestle Sa Composition comprising free amino acids
US7794744B2 (en) 2000-04-18 2010-09-14 Nestec S.A. Nutritional modules
US6391332B1 (en) 2000-04-20 2002-05-21 Baxter International, Inc. Therapeutic micronutrient composition for severe trauma, burns and critical illness
US20030187049A1 (en) 2000-07-04 2003-10-02 Dioguardi Francesco Saverio Compositions based on aminoacids, suitable for improving muscle performance
IT1320782B1 (it) 2000-07-04 2003-12-10 Professional Dietetics Srl Composizioni a base di aminoacidi, atte al trattamentodell'insufficienza cardiaca.
IT1320783B1 (it) 2000-07-04 2003-12-10 Professional Dietetics Srl Composizioni a base di aminoacidi, atte al miglioramento delleprestazioni muscolari.
US6417293B1 (en) 2000-12-04 2002-07-09 Dow Corning Corporation Thermoplastic silicone elastomers formed from polyester resins
DE10060819A1 (de) 2000-12-07 2002-06-13 Cognis Deutschland Gmbh Verwendung von Polyetheramin-Derivaten zur dauerhaften Verbesserung der Klebstoff- und/oder Beschichtungs-Kompatibilität von Polyethylen-basierten Formkörpern, Fasern und Folien
DE10060818A1 (de) 2000-12-07 2002-06-13 Cognis Deutschland Gmbh Verwendung von Polyetheraminen zur dauerhaften Verbesserung der Klebstoff- und/oder Beschichtungs-Kompatibilität von Polyethylen-basierten Formkörpern, Fasern und Folien
EP1372641A4 (en) 2001-03-05 2004-08-25 Stephen P Ernest ENTERAL FORMULATION
JPWO2002074302A1 (ja) 2001-03-15 2005-07-14 独立行政法人理化学研究所 肝機能障害改善用アミノ酸組成物
US20020193342A1 (en) 2001-05-09 2002-12-19 Hamman John P. Modifying undesirable tastes
ITTO20010580A1 (it) 2001-06-15 2002-12-15 Professional Dietetics Srl Composizioni a base di aminoacidi per il miglioramento della funzioneventricolare miocardica in pazienti affetti da diabete.
US6864230B2 (en) 2001-07-31 2005-03-08 Novartis Nutrition Ag Glutamine rich dietary composition
EP1466602A4 (en) 2001-12-25 2006-03-01 Ajinomoto Kk ORGAN FIBROSIS INHIBITORS
US7622447B2 (en) 2002-01-25 2009-11-24 Diamedica Inc. Use of glutathione synthesis stimulating compounds in reducing insulin resistance
JP2003238401A (ja) 2002-02-20 2003-08-27 Ajinomoto Co Inc 疾患の治療、改善又は予防用医薬品及び飲食品
US7338675B2 (en) 2002-05-10 2008-03-04 Tsi Health Sciences, Inc. Fenugreek seed bio-active compositions and methods for extracting same
US20050176827A1 (en) 2002-05-10 2005-08-11 Lee Steve S. Compositions and methods for glycogen synthesis
ES2524000T3 (es) 2002-06-05 2014-12-03 Teva Czech Industries S.R.O. Reducción de la reticulación de la gelatina
US20040087490A1 (en) 2002-09-20 2004-05-06 Troup John P. Nutritional compositions
US20040057983A1 (en) 2002-09-25 2004-03-25 David Schmidt Biomolecular wearable apparatus
US7037522B2 (en) 2002-09-27 2006-05-02 Western Holdings, L.L.C. Nocturnal muscle enhancing composition and method
JP2004123564A (ja) 2002-09-30 2004-04-22 Inst Of Physical & Chemical Res 中枢機能改善用アミノ酸組成物
JP2004182705A (ja) 2002-10-11 2004-07-02 Yasutoshi Koga ミトコンドリア機能異常に起因する疾患における臨床症状発現の予防・治療用組成物
US7547450B2 (en) 2002-10-24 2009-06-16 Nestec Ltd. Senior feline food
US8093292B2 (en) 2002-11-22 2012-01-10 Bionexus, Ltd. Methods for the treatment of HIV-1 related fat maldistribution, fasting hyperlipidemia and modification of adipocyte physiology
US7288570B2 (en) 2002-12-20 2007-10-30 Nutricia N.V. Stimulation of in vivo production of proteins
US20040120983A1 (en) 2002-12-23 2004-06-24 Philip Connolly Nutritional supplement
JP4989836B2 (ja) 2002-12-26 2012-08-01 大塚製薬株式会社 経口栄養剤
EP1582207A4 (en) 2002-12-26 2008-03-05 Ajinomoto Kk HEMMER FOR OUTBREAKING AND PROGREDIENCE OF LIVER CANCER
CA2516142A1 (en) 2003-03-18 2004-09-30 Novartis Ag Compositions comprising fatty acids and amino acids
US20040213838A1 (en) 2003-04-24 2004-10-28 Mazer Terrence B. Medical food tablets containing free amino acids
JP4528925B2 (ja) 2003-05-30 2010-08-25 独立行政法人理化学研究所 アミノ酸組成物及び補液
DK1638418T3 (da) 2003-06-23 2012-09-17 Nestec Sa Aminosyretilsætning til et sundt mikrobiota-økosystem
JP2005027524A (ja) 2003-07-08 2005-02-03 Ajinomoto Co Inc 経口アミノ酸組成物
WO2005017094A2 (en) 2003-08-19 2005-02-24 Bioadvantex Pharma Inc. N-acetyl compositions as adjunct therapy for treatment and prevention of cysteine/glutathione deficiency
ITTO20030789A1 (it) 2003-10-07 2005-04-08 Professional Dietetics Srl Composizione a base di amino acidi per il trattamento
ES2677868T3 (es) 2003-10-16 2018-08-07 Nestec S.A. Composición nutricional frente a los efectos secundarios de la quimioterapia o de la radioterapia
WO2005049006A1 (ja) 2003-11-21 2005-06-02 Ajinomoto Co., Inc. 糖尿病治療剤
DK1543735T3 (en) 2003-12-20 2015-11-02 Nestec Sa FOOD COMPOSITION FOR HEALTH CARE
JPWO2005072721A1 (ja) 2004-01-28 2007-09-06 味の素株式会社 局所脳血流低下に伴う神経系障害の予防または治療のための医薬組成物
WO2005082163A1 (ja) 2004-02-27 2005-09-09 Incorporated Administrative Agency National Agriculture And Food Research Organization 遊離アミノ酸を富化した食品素材及びその製造法
US20050215640A1 (en) 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
JP4815752B2 (ja) 2004-04-01 2011-11-16 味の素株式会社 アミノ酸含有飲食品
WO2005110124A1 (en) 2004-04-15 2005-11-24 Abbott Laboratories Composition and methods for nutritional management of patients with hepatic disease
CN1582912A (zh) 2004-06-10 2005-02-23 武汉启瑞科技发展有限公司 L－鸟氨酸和 l－门冬氨酸组合物
US20060002913A1 (en) 2004-06-22 2006-01-05 Gehlsen Kurt R Use of histamine and related compounds to treat disorders affecting muscle function
RU2372900C2 (ru) 2004-07-14 2009-11-20 Адзиномото Ко., Инк. Ингибитор возникновения и развития рака печени для применения у пациентов-людей с циррозом печени, положительных по вирусу гепатита с
PL1771191T3 (pl) 2004-07-19 2014-08-29 Nutricia Nv Preparat do zastosowania asparaginianu i witaminy B12 lub biotyny do regulowania poziomu ciał ketonowych
EP1637163A1 (en) 2004-09-21 2006-03-22 Andreas Kluge Indicator of therapeutic compliance
JP5177785B2 (ja) 2004-11-02 2013-04-10 味の素株式会社 周術期患者用薬剤
PT2319581E (pt) 2004-11-26 2015-06-30 Ucl Business Plc Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática
US20090048153A1 (en) 2004-12-03 2009-02-19 University Of Maryland, Baltimore Composition for treating sulfur mustard toxicity and methods of using same
JPWO2006061992A1 (ja) 2004-12-10 2008-06-05 味の素株式会社 肝疾患予防・治療用組成物
US20080114067A1 (en) 2005-01-31 2008-05-15 Takanobu Yamamoto Composition for Recovery From or Prevention of Central Nervous System Fatigue
CN1679941A (zh) 2005-02-02 2005-10-12 北京阜康仁生物制药科技有限公司 一种由牛磺酸和治疗肝病的药物组成的复方制剂及其制备方法
CA2537647A1 (en) 2005-03-01 2006-09-01 Six Star Formulations Ltd. Supplemental dietary composition for supporting muscle growth, recovery and strength
US20080193505A1 (en) 2005-03-15 2008-08-14 Nestec S.A. Nutritional Compositions For Modulating Vitamin C Bio-Availability
WO2006102451A2 (en) 2005-03-21 2006-09-28 Abbott Laboratories Amino acid composition for improving glucose tolerance
US20100267831A1 (en) 2005-03-29 2010-10-21 Hisamine Kobayashi Amino Acid-Containing Composition for Preventing or Remedying Decrease in the Skeletal Muscle of Aged People
CN101175416A (zh) 2005-04-06 2008-05-07 诺瓦提斯公司 从营养方面改善葡萄糖控制和胰岛素作用的方法和组合物
US8993627B2 (en) 2005-04-21 2015-03-31 Sentient Lifesciences, Inc. N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress
WO2006134135A2 (en) 2005-06-14 2006-12-21 Nestec S.A. Nutritional method for elderly people
JPWO2006137469A1 (ja) 2005-06-22 2009-01-22 味の素株式会社 代謝型グルタミン酸受容体活性化剤
US20100104548A1 (en) 2005-06-24 2010-04-29 Albert Einstein College Of Medicine Of Yeshiva University Modulation of amino acid metabolism in the hypothalamus
EP1920770A4 (en) 2005-07-01 2010-09-29 Ajinomoto Kk THERAPEUTIC AGENT AGAINST INFLAMMATORY DISEASE AND TNF ALPHA PRODUCTION DISEASE
JP2007023921A (ja) * 2005-07-19 2007-02-01 Toyota Motor Corp 内燃機関の制御装置
JP5682990B2 (ja) 2005-08-04 2015-03-11 味の素株式会社 酸化型アルブミン低下剤
JP5067160B2 (ja) 2005-08-05 2012-11-07 味の素株式会社 肝癌発生・進展抑制剤
US8148356B2 (en) 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
US20070053955A1 (en) 2005-08-26 2007-03-08 Nestec S.A. Compositions and methods for improving cellular survival and reducing apoptosis after ischemic episode in the brain
EP1774973A1 (en) 2005-10-12 2007-04-18 Nutricia N.V. Leucine rich composition
BRPI0617824A2 (pt) 2005-10-28 2011-08-09 Nestec Sa métodos para o uso de aminoácidos de cadeia ramificada
US20080317886A1 (en) 2005-11-03 2008-12-25 Sparkman Dennis R Compositions for Preventing and Reducing Delayed Onset Muscle Soreness
US20070243211A1 (en) 2005-11-07 2007-10-18 Jaffe Russell M Compositions for regulating metabolic disorders and methods of use thereof
CN101316582A (zh) 2005-11-30 2008-12-03 雀巢技术公司 治疗肌肉损失的方法
ES2548432T3 (es) 2005-12-19 2015-10-16 Abbott Laboratories Uso de beta-hidroxi-beta-metilbutirato para modular el desequilibrio en la producción de citoquinas de tipo 1 y tipo 2
EP1971230A2 (en) 2006-01-09 2008-09-24 Nestec S.A. Treatment of stressed patients
PL1983849T3 (pl) 2006-01-20 2013-09-30 Innova Food Ab Kompozycja spożywcza zawierająca aminokwasy
US20090087540A1 (en) 2006-01-31 2009-04-02 Nestec S.A. Nutritional composition for low birth weight infants
WO2007133642A1 (en) 2006-05-11 2007-11-22 Garcia Ramon D Sport drink containing amino acids and carbohydrates
JP5100033B2 (ja) 2006-05-16 2012-12-19 大塚製薬株式会社 消化管及び腎臓の萎縮抑制剤
US20070286909A1 (en) * 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions
JP2008050277A (ja) 2006-08-22 2008-03-06 Ajinomoto Co Inc 鉄欠乏性貧血症治療用組成物
US9192593B2 (en) 2006-08-30 2015-11-24 Ajinomoto Co., Inc. Amino-acid containing composition for inhibiting accumulation of fat
WO2008046870A1 (en) 2006-10-19 2008-04-24 Nestec S.A. Long-term feed - cancer patient
US20080102137A1 (en) 2006-10-31 2008-05-01 Guffey Manning V R Composition and method for etiological treatment and prevention of diseases and/or complications associated with chronic glucose metabolism destabilization
GB0624879D0 (en) 2006-12-14 2007-01-24 Shs Int Ltd Treatment of pervasive development disorders
EP1932437A1 (en) 2006-12-15 2008-06-18 Nestec S.A. Infant formula
CN100518815C (zh) 2007-02-15 2009-07-29 北京苏里曼医药科技有限公司 一种氨基酸组合物
US20080268038A1 (en) 2007-04-26 2008-10-30 Wolfe Robert R Compositions and Approaches for Increasing Diet Induced Thermogenesis, Inducing Weight Loss and Maintaining Muscle Mass and Strength
CN101332209B (zh) 2007-06-25 2010-12-08 三菱制药（广州）有限公司 治疗肝性脑病的复方氨基酸注射液
US8455531B2 (en) 2007-09-18 2013-06-04 Thermolife International, Llc Amino acid compositions
US8466187B2 (en) 2007-09-18 2013-06-18 Thermolife International, Llc Amino acid compositions
US7777074B2 (en) 2007-09-18 2010-08-17 Thermolife International, Llc Amino acid compounds
KR100970664B1 (ko) 2007-10-11 2010-07-15 한화제약주식회사 Ｌ-오르니틴-ｌ-아스파테이트를 함유한 겔제의 제조방법 및그 겔제
EP2057905A1 (en) 2007-11-12 2009-05-13 TIMA Foundation Composition for moderating Triglyceride and Cholesterol Levels
US20110077198A1 (en) 2007-11-26 2011-03-31 Michael John Tisdale Compositions and methods for inhibiting the activation of dsrna-dependent protein kinase and tumor growth inhibition
CN101214050B (zh) 2007-12-28 2011-08-31 叶高山 一种具有提神、抗疲劳、醒酒功能的保健饮料
CA2709660C (en) 2008-01-04 2018-06-05 Nestec S.A. Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions
US7790688B2 (en) 2008-01-11 2010-09-07 Healthspan Solutions, Llc Compositions and methods for increasing muscle mass, strength, and functional performance in the elderly
US20090186098A1 (en) 2008-01-18 2009-07-23 Jose Briceno Sports drink composition
EP2095728B1 (en) 2008-01-25 2011-09-07 Cesar Gallia s.r.l. Amino acid concentrate in aqueous gel and fatigue-relieving drink obtainable by diluting said concentrate in water
US8716249B2 (en) 2008-01-31 2014-05-06 Energy Light Llc Compositions and methods for improving cardiovascular health
US20090203606A1 (en) 2008-02-05 2009-08-13 Wolfe Robert R Systems for and Methods of use of Therapeutic Nutrition for the Management of Age-Associated and Age-Specific Health Conditions of the Elderly
ES2483735T3 (es) 2008-02-07 2014-08-07 Nestec S.A. Composiciones y métodos para influir en la recuperación después de una actividad física intensa
EP2098124A1 (en) 2008-03-03 2009-09-09 Nestec S.A. Carbohydrate gel
EP2098126A1 (en) 2008-03-03 2009-09-09 Nestec S.A. Carbohydrate Bar
CN102316730A (zh) 2008-05-09 2012-01-11 天雅瑞药业有限公司 用于减轻全身性炎症和/或血管炎症的n-乙酰半胱氨酸(nac)的控释
CA2727088A1 (en) 2008-06-04 2009-12-10 Phenolics, Llc Enteric-coated formulations of polyethylene glycol and one or more soluble amino acids for oral ingestion and enhanced uptake of same
US20100021573A1 (en) * 2008-07-22 2010-01-28 Michael J Gonzalez Compositions and methods for the prevention of cardiovascular disease
WO2010033425A2 (en) 2008-09-19 2010-03-25 Nestec S.A. Nutritional support to prevent or moderate bone marrow paralysis or neutropenia during anti-cancer treatment
EP2165713B1 (en) 2008-09-19 2012-11-14 Nestec S.A. Whey and thymus function
EP2351562A4 (en) 2008-10-27 2012-09-05 Ajinomoto Kk SOLID SOLUTION OF VALIN, ISOLEUCIN AND LEUCIN AND MANUFACTURING PROCESS THEREFOR
US8362080B2 (en) 2008-12-18 2013-01-29 Baylor College Of Medicine Increasing glutathione levels for therapy
US9314444B2 (en) 2009-01-12 2016-04-19 Biokier, Inc. Composition and method for treatment of NASH
HUE034551T2 (en) 2009-01-12 2018-02-28 Biokier Inc Composition and method for treatment of diabetes
US20120178672A1 (en) 2009-03-18 2012-07-12 Wolfe Robert R Compositions and Methods for Sparing Muscle in Renal Insufficiency and During Hemodialysis
WO2010108542A1 (en) 2009-03-25 2010-09-30 Nestec S.A. A natural taste enhancing savoury base and a process for its preparation
CN106810464B (zh) 2009-04-03 2019-01-22 欧塞拉治疗有限公司 L-鸟氨酸苯乙酸盐及其制备方法
WO2010126353A1 (en) 2009-04-27 2010-11-04 N.V. Nutricia Pea-based protein mixture and use thereof in a liquid nutritional composition suitable for enteral feeding
US8703719B1 (en) 2009-05-18 2014-04-22 Bio-Engineered Supplements And Nutrition, Inc. Method and composition for improved muscle performance
ES2517340T3 (es) 2009-06-08 2014-11-03 Ucl Business Plc Tratamiento de la hipertensión portal usando L-ornitina y fenilacetato
WO2010143939A1 (en) 2009-06-09 2010-12-16 N.V. Nutricia Nutrition for improving muscle strength in elderly
RU2012105901A (ru) 2009-07-20 2013-08-27 Нестек С.А. Способы снижения потери функционального состояния
WO2011030104A1 (en) 2009-09-09 2011-03-17 Rajiv Jalan Phenylacetate and/or phenylbutyrate (not ornithine) for reducing portal blood pressure
CN101664384B (zh) 2009-09-18 2011-09-14 杭州市第六人民医院 N-乙酰半胱氨酸盐木糖醇注射液及其制备方法和应用
MX2012003459A (es) 2009-09-23 2012-05-22 Biokier Inc Composicion y metodo para el tratamiento de la diabetes.
WO2011044230A2 (en) 2009-10-06 2011-04-14 Goldstein Glenn A N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions
WO2011043647A1 (en) 2009-10-09 2011-04-14 N.V. Nutricia Amino acid composition with improved dispersibility
PL2327315T3 (pl) 2009-11-29 2014-03-31 Nestec Sa Protokoły dawkowania dla zwiększenia syntezy białka u osób aktywnych
EP2327316B1 (en) 2009-11-29 2016-11-16 Premier Nutrition Corporation Method of enhancing muscle protein synthesis
JP2011132174A (ja) 2009-12-24 2011-07-07 Kirin Holdings Co Ltd 持久力向上剤
WO2011078654A1 (en) 2009-12-24 2011-06-30 N.V. Nutricia Low-caloric high-protein nutritional composition for the stimulation of muscle protein synthesis
EP2544555B1 (en) 2010-03-12 2018-05-16 Nestec S.A. Compositions for masking the flavor of leucine and methods for making same
WO2011119023A1 (en) 2010-03-26 2011-09-29 N.V. Nutricia Low protein infant formula with increased essential amino acids
JP2013529193A (ja) 2010-04-26 2013-07-18 ネステク ソシエテ アノニム 非経口栄養から経腸栄養へ離脱させるための栄養組成物及び方法
US8840950B2 (en) 2010-05-26 2014-09-23 Jacqueline M. Hibbert Compositions of nutrition supplementation for nutritional deficiencies and method of use therefore
WO2012005568A1 (en) 2010-07-07 2012-01-12 N.V. Nutricia Nutritional composition for the stimulation of muscle protein synthesis
KR101213825B1 (ko) 2010-07-16 2012-12-18 서울대학교산학협력단 세린을 유효성분으로 함유하는 지방간 질환의 예방 및 치료용 조성물
EP2596112A4 (en) 2010-07-21 2015-01-21 Cumberland Pharmaceuticals Inc ACETYCYSTEIN COMPOSITIONS AND USE METHOD THEREFOR
US20120020947A1 (en) 2010-07-22 2012-01-26 Northern Innovations And Formulations Corp. Compositions and methods for increasing lean muscle mass after exercise
CN101912394B (zh) 2010-08-06 2013-11-06 岳茂兴 一种用于治疗凝血障碍出血的药物组合物及其用途
EP2625162B1 (en) 2010-10-06 2019-03-13 Ocera Therapeutics, Inc. Methods of making l-ornithine phenyl acetate
EP2444083A1 (en) 2010-10-21 2012-04-25 Nestec S.A. Cysteine and food intake
CN103338658A (zh) 2010-12-22 2013-10-02 雅培制药有限公司 含有β-羟基-β甲基丁酸钙和共轭亚油酸的营养型产品
EP2658535A1 (en) 2010-12-27 2013-11-06 Abbott Laboratories Methods for facilitating muscle recovery after a period of disuse using beta-hydroxy-beta-methylbutyrate
WO2012097061A1 (en) 2011-01-13 2012-07-19 Abbott Laboratories Nutritional compositions and methods for improving skeletal muscle protein metabolism
JP2014504605A (ja) 2011-01-25 2014-02-24 ネステク ソシエテ アノニム 動物の視覚系の劣化を治療、緩和又は予防するための方法及び組成物
EP2685987B1 (en) 2011-03-18 2019-04-24 Nestec S.A. Compositions and methods useful for ameliorating age related maladies
US11235008B2 (en) 2011-03-31 2022-02-01 Ganeden Biotech, Inc. Probiotic sports nutrition compositions
CN102327259A (zh) 2011-03-31 2012-01-25 姜国辉 具有显著化学性肝损伤保护功能的复合生物制剂
SG193926A1 (en) 2011-04-12 2013-11-29 Nestec Sa Nutritional compositions including branched chain fatty acids and methods of using same
JP2014512372A (ja) 2011-04-18 2014-05-22 ネステク ソシエテ アノニム α−ＨＩＣＡ及びエイコサペンタエン酸を含有する栄養組成物
US20120270860A1 (en) 2011-04-19 2012-10-25 Gihyun Yoon Methods for treating or preventing alcohol-related disorders or craving-related disorders
JP2014513527A (ja) 2011-04-21 2014-06-05 ネステク ソシエテ アノニム パフォーマンス向上のための栄養組成物並びにその作製及び使用方法
US8828426B2 (en) 2011-06-07 2014-09-09 Zx Pharma, Llc Multiparticulate L-carnitine compositions and related methods
US20140135396A1 (en) 2011-07-05 2014-05-15 Beth Israel Deaconess Medical Center, Inc. Treatment of Acetaminophen-Induced Liver Damage by the Administration of Modulators of Nitric Oxide
JP6431670B2 (ja) 2011-08-08 2018-11-28 味の素株式会社 筋肉疲労の回復を促進するためのアミノ酸含有組成物
HK1199378A1 (en) 2011-08-19 2015-07-03 Musclepharm Corporation Compositions and methods for use in promoting lean body mass
EP2574333B1 (en) 2011-09-27 2017-01-11 Friulchem SpA N-acetylcysteine effervescent tablet and its therapeutical applications
EP2580967A1 (en) 2011-10-11 2013-04-17 Nestec S.A. Accelerating muscle recovery after immobilization-induced muscle atrophy
EP2583563A1 (en) 2011-10-21 2013-04-24 Nestec S.A. Whey protein micelles against muscle atrophy and sarcopenia
EP2583565A1 (en) 2011-10-21 2013-04-24 Nestec S.A. Use of whey protein micelles for enhancing energy expenditure and satiety
US9364463B2 (en) 2011-11-18 2016-06-14 Board Of Trustees Of The University Of Arkansas Use of amino acid supplementation for improved muscle recovery
BR112014011898A2 (pt) 2011-11-21 2017-05-16 Emmaus Medical Inc métodos e composições para o tratamento de diabetes e sintomas relacionados
WO2013081154A1 (ja) 2011-12-02 2013-06-06 味の素株式会社 キナーゼ阻害剤の副作用低減剤
JP6192543B2 (ja) 2012-01-19 2017-09-06 昇一 城武 植物病原細菌用抗菌剤
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
US20150119339A1 (en) 2012-06-11 2015-04-30 Abbott Laboratories Use of hmb to improve health outcomes for hospitalized patients
CN104582506B (zh) 2012-07-31 2016-10-19 雀巢产品技术援助有限公司 用于促进患有炎症性肠病(ibd)的患者的肌肉骨骼健康的营养组合物
CA2884717A1 (en) 2012-09-14 2014-03-20 Nestec S.A. Novel flavour compositions with improved flavour and/or flavour shelf-life
US8747921B2 (en) 2012-09-19 2014-06-10 Quality Ip Holdings, Inc. Methods for improving health in humans
US9198889B2 (en) 2012-09-19 2015-12-01 Quality IP Holdings, LLC Methods for treating post-traumatic stress disorder
US9066953B2 (en) 2012-09-20 2015-06-30 Quality IP Holdings, LLC Methods for increasing endurance and fat metabolism in humans
CN102961377A (zh) 2012-11-08 2013-03-13 湖北一半天制药有限公司 复方氨基酸注射液（20aa）的制备方法
ES2633769T3 (es) 2012-12-04 2017-09-25 Nestec S.A. Hexanoilglicina como biomarcador para la predisposición al aumento de peso y a la obesidad
MX369877B (es) 2013-02-04 2019-11-25 Seres Therapeutics Inc Composiciones y metodos.
MX361647B (es) 2013-03-11 2018-12-13 Univ Florida Materiales y métodos para mejorar la función pulmonar y para la prevención y/o tratamiento de complicaciones pulmonares inducidas por radiación.
SG11201507046UA (en) 2013-03-15 2015-10-29 Nusirt Sciences Inc Leucine and nicotinic acid reduces lipid levels
JP2016516419A (ja) 2013-03-26 2016-06-09 プレミア・ニュートリション・コーポレイション 同時トレーニングに続いて筋タンパク質合成を高めるための方法
EP2986156B2 (en) 2013-04-15 2020-06-03 Société des Produits Nestlé S.A. Use of whey protein in combination with electrical muscle stimulation
US20160058726A1 (en) 2013-04-16 2016-03-03 The Children's Hospital Of Philadelphia Compositions and methods for the treatment of brain injury
US20140357576A1 (en) 2013-05-31 2014-12-04 Nestec S.A. Methods for enhancement of muscle protein synthesis
JP6677639B2 (ja) 2013-06-28 2020-04-08 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 運動パフォーマンスを高める組成物及び方法
WO2015015149A1 (en) 2013-07-31 2015-02-05 Leeds Metropolitan University Dietary supplement
SG11201602012RA (en) 2013-09-25 2016-04-28 Pronutria Inc Compositions and formulations for maintaining and increasing muscle mass, strength, and performance and methods of production and use thereof
US20180125926A1 (en) 2013-09-25 2018-05-10 Axcella Health Inc. Compositions and Formulations and Methods of Production and Use Thereof
AU2014333977B2 (en) 2013-10-09 2019-12-19 Société des Produits Nestlé S.A. Compositions comprising citrulline and leucine and their use in the treatment of diabetes and metabolic syndrome
EP3060231A1 (en) 2013-10-23 2016-08-31 The Whitehead Institute for Biomedical Research Mtorc1 modulation by amino acids and uses thereof
CA2939833A1 (en) 2014-02-27 2015-09-03 Nusirt Sciences, Inc. Compositions and methods for the reduction or prevention of hepatic steatosis
GB2523578A (en) 2014-02-28 2015-09-02 Daniel Nelson A nutritional supplement
WO2015161448A1 (en) 2014-04-22 2015-10-29 Wuhan Ll Science And Technology Development Co., Ltd. Ornithine-containing or aspartate-containing compositions and the uses thereof
CN105092753B (zh) 2014-05-20 2016-09-07 中国科学院大连化学物理研究所 组合型胺类代谢标志物的应用及试剂盒
WO2016003263A1 (en) 2014-07-01 2016-01-07 N.V. Nutricia Amino acid based diet with improved taste
US10217645B2 (en) 2014-07-25 2019-02-26 Versum Materials Us, Llc Chemical mechanical polishing (CMP) of cobalt-containing substrate
US20160158305A1 (en) 2014-09-19 2016-06-09 Chip E. Thomson Additives and supplements
BR112017005762B1 (pt) 2014-10-14 2021-10-05 Société des Produits Nestlé S.A. Composição compreendendo uma fonte de proteína, e um antioxidante e seu uso
KR20230018526A (ko) 2014-11-24 2023-02-07 유씨엘 비즈니스 리미티드 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료
US10272059B2 (en) 2014-12-04 2019-04-30 Professional Dietetics S.P.A. Aminoacid-based composition for fibroelastin recovery in dermal connective tissues
US10894024B2 (en) 2014-12-08 2021-01-19 Synaptamine, Inc. Anti-RDS compounds and method of manufacture and administration thereof to induce dopamine homeostatis
EP3034074A1 (en) 2014-12-18 2016-06-22 Universitat De València, Estudi General Compound for treatment of myotonic dystrophy type 1
AU2016208457B2 (en) 2015-01-23 2022-03-24 Société des Produits Nestlé S.A. Method for determining the distinctive nutritional requirements of a patient
US20170368026A1 (en) 2015-01-23 2017-12-28 Nestec S.A. Promotion of healing of intestinal mucosa using proline, serine and threonine
EP3247343A1 (en) 2015-01-23 2017-11-29 Nestec S.A. Nutritional composition useful in the treatment of ibd patients
JP2018504406A (ja) 2015-01-23 2018-02-15 ネステク ソシエテ アノニム セリンを用いた炎症の治療又は予防
WO2016121829A1 (ja) 2015-01-27 2016-08-04 昇一 城武 ナノ粒子を有効成分とする皮膚炎の治療又は予防剤
CN107205962B (zh) 2015-02-13 2020-10-02 雀巢产品有限公司 手术诱导的恶病质的治疗或预防以及/或者骨髓来源的抑制性细胞和促炎性细胞因子的表达
US20180036270A1 (en) 2015-02-13 2018-02-08 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College A method of protecting against carbonyl stress induced ischemia-reperfusion injury in the diabetic brain via administration of n-acetylcysteine
FR3032883B1 (fr) * 2015-02-24 2017-03-17 International Nutrition Res Company Composition pour la prevention et le traitement de la steatose et de la steatohepatite metaboliques
US20160302451A1 (en) 2015-04-16 2016-10-20 Michael Hudnall Medical Food for Patients with Chronic Liver Disease
HK1251149A1 (zh) 2015-04-20 2019-01-25 Ocera Therapeutics, Inc. L-鸟氨酸苯乙酸盐制剂
US10123985B2 (en) 2015-06-08 2018-11-13 Whitehead Institute For Biomedical Research Therapeutic strategies for treating mitochondrial disorders
CN107708446A (zh) 2015-06-22 2018-02-16 雀巢产品技术援助有限公司 用于增强动物体内神经形成的组合物和方法
MX380541B (es) 2015-06-30 2025-03-12 Soc Des Produits Nestle S A Star Composición adecuada para proteger microorganismos.
CA3185891A1 (en) 2015-07-15 2017-01-19 Unigen, Inc. Compositions, methods, and medical compositions for treatment of and maintaining the health of the liver
MX382576B (es) 2015-08-14 2025-03-13 Soc Des Produits Nestle S A Star Composiciones alimenticias semihúmedas que mantienen una textura blanda.
JP6990170B2 (ja) 2015-08-18 2022-01-12 オセラ セラピューティクス， インコーポレイテッド Ｌ－オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも１つと組み合わせて用いる筋肉喪失の治療および予防
WO2017033272A1 (ja) 2015-08-25 2017-03-02 昇一 城武 優れた植物病害防除効果を有する菌類用抗菌剤
US20170079897A1 (en) 2015-09-20 2017-03-23 Matthew Brissette MINUS Composition for hair application and methods of hair care
JP6989495B2 (ja) 2015-09-25 2022-01-05 オセラ セラピューティクス， インコーポレイテッド Ｌ−オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも１つと組み合わせて用いる神経細胞喪失の治療および予防
US20170196944A1 (en) 2015-09-28 2017-07-13 Robert Portman Method to reduce muscle atrophy following orthopedic surgery
WO2017083758A1 (en) 2015-11-13 2017-05-18 Ocera Therapeutics, Inc. Formulation of l-ornithine phenylacetate
US11219611B2 (en) 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate
EP3851114B1 (en) 2015-11-20 2024-10-09 Société des Produits Nestlé S.A. Composition comprising micellar whey protein, vitamin d and calcium for use in decreasing fat deposition in skeletal muscle in an elderly individual
CH713469B1 (de) 2015-12-21 2021-06-30 Nianjing Jianrong Bio Tech Co Ltd Zusammensetzung zum Behandeln von Motoneuron-Erkrankungen
US20190000866A1 (en) 2016-01-08 2019-01-03 Colonaryconcepts Llc Food based delivery of therapeutic agent for treatment of hepatic encephalopathy
GB201600990D0 (en) 2016-01-19 2016-03-02 Abbott Lab Pharmaceutical or nutritional combination
EP3454665A4 (en) 2016-05-11 2020-02-19 Tsubo Solutions Pty Ltd CONFECTIONERY PRODUCT
EP3463321A1 (en) 2016-05-27 2019-04-10 Nestec S.A. Nutritional composition for treating or preventing impaired mobility
PL238958B1 (pl) 2016-06-29 2021-10-25 Olimp Laboratories Spolka Z Ograniczona Odpowiedzialnoscia Kompozycja aminokwasowa do stosowania przed wysiłkiem fizycznym
US20180015122A1 (en) 2016-07-14 2018-01-18 Companion Supplements, LLC Pharmaceutical composition effective in preventing adverse effects associated with the use of glucocorticoids
US11033522B2 (en) 2016-08-09 2021-06-15 David C Scott Free amino acid preparation and uses thereof
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
JOP20190147A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض واضطرابات العضلات
CN106632605B (zh) 2016-12-22 2020-06-16 浙江海洋大学 利用金枪鱼下脚料制备的具有肝损伤修复作用的活性肽
SE540582C2 (en) 2016-12-22 2018-10-02 Scandibio Therapeutics Ab Substances for treatment of fatty liver-related conditions
EP3570826A4 (en) 2017-01-19 2020-09-23 Otologic Pharmaceutics, Inc. N-ACETYLCYSTEIN FORMULATIONS AND THEIR USES
WO2018201024A1 (en) 2017-04-28 2018-11-01 Axcella Health Inc. Amino acid compositions and their use for the treatment of traumatic brain injury
CN107242552A (zh) 2017-07-07 2017-10-13 上海东锦食品集团有限公司 具有缓解体力疲劳及增强免疫力功能的保健食品组合物
WO2019036471A1 (en) 2017-08-14 2019-02-21 Axcella Health Inc. AMINO ACIDS BRANCHED FOR THE TREATMENT OF LIVER DISEASE
US20190046486A1 (en) 2017-08-14 2019-02-14 Axcella Health Inc. Compositions and methods for the treatment of neuronal injury
CN108041501A (zh) 2017-12-22 2018-05-18 北京康比特体育科技股份有限公司 一种促进疲劳恢复的蛋白组合物及其制备方法
JP2021527669A (ja) 2018-06-20 2021-10-14 アクセラ・ヘルス・インコーポレイテッドＡｘｃｅｌｌａ Ｈｅａｌｔｈ Ｉｎｃ． 線維症の軽減又は治療のための組成物及び方法
US11298332B2 (en) 2018-06-20 2022-04-12 Axcella Health Inc. Compositions for therapy and health containing amino acids with bitter taste
WO2019246221A1 (en) 2018-06-20 2019-12-26 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders
EP3810123A1 (en) 2018-06-20 2021-04-28 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
US20210260010A1 (en) 2018-06-20 2021-08-26 Axcella Health Inc. Compositions and methods for the reduction or treatment of inflammation
BR112020025831A2 (pt) 2018-06-20 2021-03-23 Axcella Health Inc. métodos de fabricação de composições de aminoácidos
MA52953A (fr) 2018-06-20 2021-04-28 Axcella Health Inc Compositions et procédés pour la réduction ou le traitement de la résistance à l'insuline et d'états métaboliques
CU20200106A7 (es) 2018-06-20 2021-08-06 Axcella Health Inc Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
CN108524453A (zh) 2018-07-05 2018-09-14 扬子江药业集团广州海瑞药业有限公司 一种门冬氨酸鸟氨酸的药物组合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001056402A2 (en) * 2000-02-01 2001-08-09 Muscletech Research And Development Inc. Alpha lipoic acid based food supplement to increase lean muscle mass and strength
EP1541141A1 (en) * 2002-08-30 2005-06-15 Ajinomoto Co., Inc. Therapeutic agent for hepatic disease
WO2005084323A2 (en) * 2004-03-02 2005-09-15 Technical Sourcing International, Inc. Compositions of bio-active compounds from fenugreek seed and methods for producing same
WO2011097273A1 (en) * 2010-02-02 2011-08-11 Martek Biosciences Corporation Methods and compositions for treating non-alcoholic fatty liver disease with docosahexaenoic acid and n-acetyl lcystenine
EP2792354A2 (en) * 2011-03-16 2014-10-22 Obshchestvo S Ogranichennoj Otvetstvennostju «Biotekhnologii Pyshchino» Composition of protectors of acute and chronic hepatic encephalopathy and method for treating acute and chronic hepatic encephalopathy

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
COOL B ET AL., CELL METAB, 2006
FOLCH J. ET AL., J. BIOL. CHEM., vol. 226, 1957, pages 497
GIDEON SMITH: "Animal Models of Cutaneous and Hepatic Fibrosis", PROGRESS IN MOLECULAR BIOLOGY AND TRANSLATIONAL SCIENCE, vol. 105, pages 371 - 408
KAWANO Y; COHEN DE, J GASTROENTEROL, 2013
KLEINER D.E. ET AL., HEPATOLOGY, vol. 41, 2005, pages 1313
KLEINER ET AL., HEPATOLOGY, vol. 41, no. 6, 2005, pages 1313 - 21
LEFEBVRE E ET AL., PLOS ONE, 2016
NAGANUMA A ET AL: "SUN-P050: Effect of the Medical Walking and Leucine Enriched Amino Acid Containing Food for Female Non-Alcoholic Fatty Liver Disease : Randomized Controlled Trial", CLINICAL NUTRITION, vol. 35, September 2016 (2016-09-01), XP029729663, ISSN: 0261-5614, DOI: 10.1016/S0261-5614(16)30393-4 *
PETERSON RG ET AL., PLOS ONE, 2017
SAITO K. ET AL., SCI REP, vol. 5, 2015, pages 12466
SELLMANN CATHRIN ET AL: "Oral arginine supplementation protects female mice from the onset of non-alcoholic steatohepatitis", AMINO ACIDS, SPRINGER VERLAG, AU, vol. 49, no. 7, 5 August 2016 (2016-08-05), pages 1215 - 1225, XP036258517, ISSN: 0939-4451, [retrieved on 20170422], DOI: 10.1007/S00726-017-2423-4 *
SETSHEDI M ET AL: "S1846 N-Acetylcysteine Improves Hepatic Insulin Resistance Associated With High-Fat Diet and Alcohol-Induced Steatohepatitis", GASTROENTEROLOGY, W.B. SAUNDERS CO, US, vol. 138, no. 5, 1 May 2010 (2010-05-01), pages S - 801, XP027026219, ISSN: 0016-5085, [retrieved on 20100427] *
SHRESTHA NIRAJAN ET AL: "Glutamine inhibits CCl4induced liver fibrosis in mice and TGF-[beta]1 mediated epithelial-mesenchymal transition in mouse hepatocytes", FOOD AND CHEMICAL TOXICOLOGY, PERGAMON, GB, vol. 93, 29 April 2016 (2016-04-29), pages 129 - 137, XP029563064, ISSN: 0278-6915, DOI: 10.1016/J.FCT.2016.04.024 *
SITCHERAN R; COMB WC; COGSWELL PC; BALDWIN AS: "Essential role for epidermal growth factor receptor in glutamate receptor signaling to NF-kappaB", MOL CELL BIOL, vol. 28, no. 16, 9 June 2008 (2008-06-09), pages 5061 - 70
TEUFEL A ET AL., GASTROENTEROLOGY, 2016
WISHART DS; TZUR D; KNOX C ET AL.: "HMDB: the Human Metabolome Database", NUCLEIC ACIDS RES, vol. 35, January 2007 (2007-01-01), pages D521 - 6
WISHART DS; TZUR D; KNOX C ET AL.: "HMDB: the Human Metabolome Database", NUCLEIC ACIDS RES., vol. 35, January 2007 (2007-01-01), pages D521 - 6
WOBSER H ET AL., CELL RES, 2009

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11602511B2 (en) 2016-12-19 2023-03-14 Axcella Health Inc. Amino acid compositions and methods for the treatment of liver diseases
US10238617B2 (en) 2016-12-19 2019-03-26 Axcella Health Inc. Amino acid compositions and methods for the treatment of liver diseases
US10471034B2 (en) 2016-12-19 2019-11-12 Axcella Health Inc. Amino acid compositions and methods for the treatment of liver diseases
US11129804B2 (en) 2016-12-19 2021-09-28 Axcella Health Inc. Amino acid compositions and methods for the treatment of liver diseases
US10201513B2 (en) 2016-12-19 2019-02-12 Axcella Health Inc. Amino acid compositions and methods for the treatment of liver diseases
US11617731B2 (en) 2017-04-28 2023-04-04 Axcella Health, Inc. Amino acid compositions and their use for the treatment of traumatic brain injury
WO2019036442A1 (en) * 2017-08-14 2019-02-21 Axcella Health Inc. AMINO ACIDS BRANCHED FOR THE TREATMENT OF NEURONAL INJURY
US10660870B2 (en) 2017-08-14 2020-05-26 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting
US10682325B2 (en) 2017-08-14 2020-06-16 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting
US11571404B2 (en) 2017-08-14 2023-02-07 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting
US10596136B2 (en) 2018-06-20 2020-03-24 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
US11833127B2 (en) 2018-06-20 2023-12-05 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
US10973793B2 (en) 2018-06-20 2021-04-13 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
KR102395036B1 (ko) 2019-07-30 2022-05-09 주식회사 고바이오랩 비알코올성 지방간 질환의 예측 또는 진단용 키트, 및 진단방법
KR102401535B1 (ko) * 2019-07-30 2022-05-24 주식회사 고바이오랩 간 손상 예방, 개선, 또는 치료용 조성물
KR20210014609A (ko) * 2019-07-30 2021-02-09 주식회사 고바이오랩 비알코올성 지방간 질환의 예측 또는 진단용 키트, 및 진단방법
KR20210014605A (ko) * 2019-07-30 2021-02-09 주식회사 고바이오랩 간 손상 예방, 개선, 또는 치료용 조성물
WO2021020923A1 (ko) * 2019-07-30 2021-02-04 주식회사 고바이오랩 간 손상 예방, 개선, 또는 치료용 조성물 및 간 손상 예방, 개선, 또는 치료방법
RU2810601C2 (ru) * 2019-07-30 2023-12-27 Кобиолабс, Инк. Композиция и способ для предотвращения, снятия симптомов или терапевтического воздействия на поражение печени
US12274718B2 (en) 2019-07-30 2025-04-15 Kobiolabs, Inc. Composition and method for preventing, alleviating, or treating liver injury
US20230203079A1 (en) * 2020-05-15 2023-06-29 Beijing Guanghe Original Technology Co., Ltd. Amino Acid Composition and Method for Catalytic Synthesis of Amino Acid by Means of Energy Radiation
WO2022266480A1 (en) 2021-06-17 2022-12-22 Axcella Health Inc. Methods of predicting liver fat content and uses thereof
WO2024026307A1 (en) 2022-07-25 2024-02-01 Axcella Health Inc. Biomarker for long covid and fatigue
WO2024030909A1 (en) 2022-08-01 2024-02-08 Axcella Health Inc. Biomarkers of amino acid composition treatment response in long covid

Also Published As

Publication number Publication date
JOP20190146A1 (ar) 2019-06-18
CA3046551A1 (en) 2018-06-28
US20180169044A1 (en) 2018-06-21
PH12019501414A1 (en) 2019-10-28
TW201834645A (zh) 2018-10-01
CN110087647A (zh) 2019-08-02
EP3554492A1 (en) 2019-10-23
IL267480A (en) 2019-08-29
US20200330417A1 (en) 2020-10-22
US20180207118A1 (en) 2018-07-26
IL284371A (en) 2021-07-29
US20180169045A1 (en) 2018-06-21
US10238617B2 (en) 2019-03-26
US11129804B2 (en) 2021-09-28
CO2019006291A2 (es) 2019-06-28
CU20190058A7 (es) 2020-02-04
IL284371B (en) 2022-10-01
JP2023029946A (ja) 2023-03-07
AU2017382170B2 (en) 2023-11-30
ZA201903580B (en) 2021-08-25
TWI777999B (zh) 2022-09-21
IL284371B2 (en) 2023-02-01
US10201513B2 (en) 2019-02-12
JP2020504108A (ja) 2020-02-06
IL296614A (en) 2022-11-01
MX2022013517A (es) 2022-11-16
IL267480B (en) 2021-07-29
PE20191136A1 (es) 2019-09-02
US20180296516A1 (en) 2018-10-18
KR20190099242A (ko) 2019-08-26
BR112019012529A2 (pt) 2019-11-19
CN115814053A (zh) 2023-03-21
US20190105294A1 (en) 2019-04-11
US11602511B2 (en) 2023-03-14
US20240041810A1 (en) 2024-02-08
ECSP19043710A (es) 2019-07-31
US10471034B2 (en) 2019-11-12
MA51451A (fr) 2019-10-23
SG10201913946WA (en) 2020-03-30
MX2019007351A (es) 2019-09-05
CL2019001686A1 (es) 2019-08-30
AU2017382170A1 (en) 2019-06-13
CN110087647B (zh) 2023-06-16

Similar Documents

Publication Publication Date Title
US11602511B2 (en) Amino acid compositions and methods for the treatment of liver diseases
US20240238232A1 (en) Compositions and methods for the reduction or treatment of insulin resistance and metabolic conditions
Jiang et al. Sarmentosin promotes USP17 and regulates Nrf2-mediated mitophagy and cellular oxidative stress to alleviate APAP-induced acute liver failure
US20190388377A1 (en) Compositions and methods for the treatment of liver diseases and disorders
EP3810276A1 (en) Compositions and methods for the reduction or treatment of inflammation
Kim et al. Metabolic regulation of immunological aging
US11737999B2 (en) Amino acid compositions and methods for the treatment of post-acute sequelae of COVID-19
US20210275480A1 (en) Compositions and methods for the reduction or treatment of fibrosis
OA19827A (en) Amino acid compositions and methods for the treatment of liver diseases.
Kannur Amino Acid Profile in Chronic Periodontitis and Aggressive Periodontitis Patients-A Clinico Biochemical Study

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17829105

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3046551

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2017382170

Country of ref document: AU

Date of ref document: 20171219

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: NC2019/0006291

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2019533079

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 122021024095

Country of ref document: BR

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019012529

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: NC2019/0006291

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 20197020657

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: DZP2019000371

Country of ref document: DZ

ENP Entry into the national phase

Ref document number: 2017829105

Country of ref document: EP

Effective date: 20190719

ENP Entry into the national phase

Ref document number: 112019012529

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20190618

WWE Wipo information: entry into national phase

Ref document number: 519402108

Country of ref document: SA

WWW Wipo information: withdrawn in national office

Ref document number: 296614

Country of ref document: IL